Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.
Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.
复制标题
剂量调整BFM-90方案治疗T细胞淋巴母细胞淋巴瘤患者的生存和预后分析
DOI：
10.18632/aging.204008
复制
发表时间：
2022-04-10
期刊：
影响因子：
5.2
通讯作者：
Xie, Yan
中科院分区：
文献类型：
--
作者：
Yu, Hui;Mi, Lan;Qi, Fei;Wang, Xing;Ye, Yingying;Li, Miaomiao;Wang, Dedao;Ding, Ning;Wang, Xiaogan;Song, Yuqin;Zhu, Jun;Xie, Yan
我们的目的是研究在我们中心接受剂量调整的Berlin-Frankfurt-Münster（BFM）-90方案作为一线治疗的T细胞淋巴母细胞性淋巴瘤（T-LBL）患者的长期预后和预后因素。共145例接受一线剂量调整BFM-90治疗的T-LBL患者进行了回顾性分析。采用条件生存分析评价患者的长期预后。应用受试者工作特征（ROC）曲线确定嗜中性粒细胞/淋巴细胞比值（NLR）的最佳临界值。总体估计3年总生存期（OS）和无进展生存期（PFS）率分别为66.8%和58.4%。条件生存分析显示，对于完成治疗后生存3年和5年或更长时间的患者，估计随后的3年OS分别增加至85.7%和94.3%。BFM-90方案后接受巩固APBSCT（自体外周血干细胞移植）的患者3年OS上级非APBSCT患者（79.1% vs. 33.4%，p<0.001）。我们还通过多变量分析发现，基线NLR ≥4.95与OS（HR=2.75，95% CI 1.55-4.89，p=0.015）和PFS（HR=2.07，95% CI 1.25-4.96，p=0.021）呈负相关。结论：一线剂量调整BFM-90治疗的T-LBL患者的生存概率显著提高，因为患者每多存活一年。在剂量调整的BFM-90治疗后增加巩固APBSCT为这些患者带来了进一步的生存益处。在我们的研究中，基线NLR ≥4.95是T-LBL患者的独立风险因素。
We aimed to investigate the long-term prognosis and prognostic factors of T-cell lymphoblastic lymphoma (T-LBL) patients who received dose-adjusted Berlin–Frankfurt–Münster (BFM)-90 regimen as first-line therapy in our center. A total of 145 T-LBL patients who underwent first-line dose-adjusted BFM-90 was retrospectively reviewed. Conditional survival analysis was used to evaluate the long-term prognosis of patients. Receiver operating characteristic (ROC) curve was applied to determine the optimal cut-off value for neutrophil-to-lymphocyte ratio (NLR). Estimated 3-year overall survival (OS) and progression-free survival (PFS) rates for overall were 66.8% and 58.4%, respectively. Conditional survival analysis showed that for patients having survived 3 and 5 years or more after the completion of the treatment, the estimated subsequent 3-year OS thereafter increased to 85.7% and 94.3, respectively. Patients receiving consolidation APBSCT (Autologous peripheral blood stem cell transplantation) after BFM-90 regimen had superior 3-year OS than those with non-APBSCT (79.1% vs. 33.4%, p<0.001). We also discovered that baseline NLR ≥4.95 was negatively associated with OS (HR=2.75, 95% CI 1.55-4.89, p=0.015) and PFS (HR=2.07, 95% CI 1.25-4.96, p=0.021) via multivariable analysis. Conclusions: The survival probability of T-LBL patients treated with first-line dose-adjusted BFM-90 has improved significantly as patients have survived for every additional year. The addition of consolidation APBSCT following dose-adjusted BFM-90 therapy bring further survival benefits for those patients. Baseline NLR ≥4.95 was an independent risk factor for T-LBL patients in our study.
登录
查看更多内容
影响因子：
45.3
作者：
Millot, F;Suciu, S;Otten, J
通讯作者：
Otten, J
影响因子：
10.3
作者：
Wong, F. Lennie;Teh, Jennifer Berano;Armenian, Saro H.
通讯作者：
Armenian, Saro H.
影响因子：
10.9
作者：
Capone M;Giannarelli D;Mallardo D;Madonna G;Festino L;Grimaldi AM;Vanella V;Simeone E;Paone M;Palmieri G;Cavalcanti E;Caracò C;Ascierto PA
通讯作者：
Ascierto PA
影响因子：
12.8
作者：
Freedman, Arnold
通讯作者：
Freedman, Arnold
影响因子：
6.4
作者：
Kang, Jihoon;Chang, Yoosoo;Ryu, Seungho
通讯作者：
Ryu, Seungho